Vacunación Contra el Virus del Papiloma Humano y Autoinmunidad

Abstract

Development of autoimmune diseases is a very important issue in relation to vaccines, because there is a risk that they might promote autoimmune phenomena in susceptible individuals. The risk: benefit ratio of developing autoimmune diseases after human papillomavirus (HPV) vaccination has not yet been resolved. Data available are limited to provide definitive conclusions. Given the recent increase of adverse effect reports, studies with sufficient sample size are expected in various po-pulations, aimed to confirm the safety of HPV vaccination in children with autoimmune diseases. A personalized analysis of each individual, including evaluation of personal and familial autoimmunity, may be suggested; however, there are no studies showing that this policy is cost-effective. Therefore, permanent pharmacovigilance of this vaccine is of paramount importance